WCA
APGE icon

Waypoint Capital Advisors’s Apogee Therapeutics APGE Stock Holding History

Waypoint Capital Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$36.8M Buy
+627,089
New +$30M 7.84% 2

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Waypoint Capital Advisors's APGE Position: Q3 2024 in Review

Waypoint Capital Advisors opened a new position in Apogee Therapeutics (APGE) in Q3 2024: 627,089 shares worth $36.8M. The stake represents 7.84% of the portfolio and ranks #2 among its holdings.

139 funds tracked by Wall St. Rank hold APGE as of Q3 2024.

  • Waypoint Capital Advisors held 627,089 shares of Apogee Therapeutics worth $36.8M as of Q3 2024.
  • Apogee Therapeutics was a new Waypoint Capital Advisors position in Q3 2024.
  • Apogee Therapeutics made up 7.84% of Waypoint Capital Advisors's portfolio in Q3 2024, its #2 holding.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2024.

Based on Waypoint Capital Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.